EP1924698A4 - EYE GENE THERAPY ON THE EYE USING AVALANCHE-MEDIATED TRANSFECTION - Google Patents

EYE GENE THERAPY ON THE EYE USING AVALANCHE-MEDIATED TRANSFECTION

Info

Publication number
EP1924698A4
EP1924698A4 EP06801803A EP06801803A EP1924698A4 EP 1924698 A4 EP1924698 A4 EP 1924698A4 EP 06801803 A EP06801803 A EP 06801803A EP 06801803 A EP06801803 A EP 06801803A EP 1924698 A4 EP1924698 A4 EP 1924698A4
Authority
EP
European Patent Office
Prior art keywords
avalanche
gene therapy
mediated transfection
ocular gene
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06801803A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1924698A2 (en
Inventor
Thomas W Chalberg Jr
Mark Blumenkranz
Daniel V Palanker
Alexander Vankov
Philip Huie Jr
Michael F Marmor
Michele P Calos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of EP1924698A2 publication Critical patent/EP1924698A2/en
Publication of EP1924698A4 publication Critical patent/EP1924698A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP06801803A 2005-08-15 2006-08-15 EYE GENE THERAPY ON THE EYE USING AVALANCHE-MEDIATED TRANSFECTION Withdrawn EP1924698A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70848605P 2005-08-15 2005-08-15
US36098406A 2006-02-22 2006-02-22
PCT/US2006/032249 WO2007022403A2 (en) 2005-08-15 2006-08-15 Ocular gene therapy using avalanche-mediated transfection

Publications (2)

Publication Number Publication Date
EP1924698A2 EP1924698A2 (en) 2008-05-28
EP1924698A4 true EP1924698A4 (en) 2010-12-15

Family

ID=37758427

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06801803A Withdrawn EP1924698A4 (en) 2005-08-15 2006-08-15 EYE GENE THERAPY ON THE EYE USING AVALANCHE-MEDIATED TRANSFECTION

Country Status (5)

Country Link
EP (1) EP1924698A4 (ja)
JP (1) JP2009507780A (ja)
AU (1) AU2006279395A1 (ja)
CA (1) CA2620294A1 (ja)
WO (1) WO2007022403A2 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101169B2 (en) * 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
WO2009062149A1 (en) * 2007-11-08 2009-05-14 Creighton University Methods for maintaining inner ear neurons
WO2012086702A1 (ja) * 2010-12-24 2012-06-28 タカラバイオ株式会社 遺伝子導入方法
EP2670477B1 (en) * 2011-02-01 2015-11-25 Moe Medical Devices LLC Plasma-assisted skin treatment
WO2013040542A1 (en) * 2011-09-17 2013-03-21 Moe Medical Devices Llc Systems methods and machine readable programs for electric field and/or plasma-assisted onychomycosis treatment
US9351790B2 (en) 2011-09-17 2016-05-31 M.O.E. Medical Devices Llc Electrode geometries and method for applying electric field treatment to parts of the body
JP6317927B2 (ja) 2012-01-09 2018-04-25 ムー・メディカル・デバイスズ・エルエルシーＭｏｅ Ｍｅｄｉｃａｌ Ｄｅｖｉｃｅｓ Ｌｌｃ プラズマ補助皮膚処置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BORRAS T: "RECENT DEVELOPMENTS IN OCULAR GENE THERAPY", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD, LONDON LNKD- DOI:10.1016/S0014-4835(03)00030-7, vol. 76, no. 6, 1 June 2003 (2003-06-01), pages 643 - 652, XP001155551, ISSN: 0014-4835 *
CHALBERG T W ET AL: "Novel physical methods for nonviral DNA transfection of RPE", IOVS, vol. 46, no. Suppl. S, 2005, & ANNUAL MEETING OF THE ASSOCIATION-FOR-RESEARCH-IN-VISION-AND-OPHTHALM OLOGY; FT LAUDERDALE, FL, USA; MAY 01 -05, 2005, pages 4690, XP009130924, ISSN: 0146-0404 *
CHALBERG THOMAS W ET AL: "phiC31 integrase confers genomic integration and long-term transgene expression in rat retina.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE JUN 2005 LNKD- PUBMED:15914635, vol. 46, no. 6, June 2005 (2005-06-01), pages 2140 - 2146, XP002606111, ISSN: 0146-0404 *
MILLER JASON M ET AL: "Precision and safety of the pulsed electron avalanche knife in vitreoretinal surgery.", ARCHIVES OF OPHTHALMOLOGY, vol. 121, no. 6, June 2003 (2003-06-01), pages 871 - 877, XP009130925, ISSN: 0003-9950 *
SEMKOVA IRINA ET AL: "Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1 OCT 2002 LNKD- PUBMED:12239351, vol. 99, no. 20, 1 October 2002 (2002-10-01), pages 13090 - 13095, XP002606109, ISSN: 0027-8424 *
TAMAI MAKOTO: "Progress in pathogenesis and therapeutic research in retinitis pigmentosa and age-related macular degeneration", NIPPON GANKA GAKKAI ZASSHI, vol. 108, no. 12, December 2004 (2004-12-01), pages 750 - 769, XP009140228, ISSN: 0029-0203 *

Also Published As

Publication number Publication date
WO2007022403A2 (en) 2007-02-22
JP2009507780A (ja) 2009-02-26
CA2620294A1 (en) 2007-02-22
WO2007022403A3 (en) 2010-04-22
AU2006279395A1 (en) 2007-02-22
EP1924698A2 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
HK1219863A1 (zh) 眼放射外科
IL237658A0 (en) Gene therapy for spinal cord disorders
HK1205935A1 (en) Non-lithotripsic kidney-stone therapy
EP1916974A4 (en) OPHTHALMIC INJECTOR
ZA200804918B (en) Therapeutic vaccine
GB0506147D0 (en) Therapeutic agents
GB0505437D0 (en) Therapeutic agents
GB0505725D0 (en) Therapeutic agents
EP1928504A4 (en) GENE THERAPY IN THE LIVER
EP1862153A4 (en) OPHTHALMIC CANNULA
EP1924698A4 (en) EYE GENE THERAPY ON THE EYE USING AVALANCHE-MEDIATED TRANSFECTION
GB0406728D0 (en) Gene therapy
GB0507003D0 (en) Therapeutic
IL186681A0 (en) Ophthalmic display
GB0501655D0 (en) Therapeutic use
SI1879623T1 (sl) Genska terapija za motnje hrbtenjače
IL164850A0 (en) Gene therapy for kidney diseases
EP1948085B8 (fr) Injecteur d'implant ophtalmique
IL255035A0 (en) Gene therapy for spinal cord disorders
AU2005904525A0 (en) Liver-directed Gene Therapy
GB0509340D0 (en) Gene over-expression
AU2006901311A0 (en) Liver-directed gene therapy
GB0501657D0 (en) Therapeutic use
GB0518537D0 (en) Therapeutic use
AU2004903306A0 (en) Eye treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080327

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20100422

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/87 20060101ALI20101102BHEP

Ipc: C12M 1/42 20060101ALI20101102BHEP

Ipc: C12N 15/64 20060101AFI20101102BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20101111

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110611